Lisinopril (ACE Inhibitor)

Treatment for Hypertensive heart disease

Typical Dosage: 2.5mg - 40mg daily

Effectiveness
88%
Safety Score
70%
Clinical Trials
2
Participants
1M

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
70
DangerousModerateSafe
Treatment Details
Dosage Range
2.5mg - 40mg daily
Time to Effect
2-4 weeks for full BP effect, months for cardiac remodeling
Treatment Duration
lifetime
Evidence Quality
HIGH
Number Needed to Treat (NNT)
15(Treat 15 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
10(Treat 10 patients to see 1 additional serious adverse event)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$30
Monitoring:$300
Side Effect Mgmt:$75
Total Annual:$405
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENT
ICER
$20,000/QALY
QALYs Gained
2.5
Outcome-Based Costs
Cost per Responder
$540
Comparison vs Hydrochlorothiazide (Thiazide Diuretic)
Cost Difference
+$20/year
More expensive
QALY Difference
+0.05 QALYs
Better outcomes
Dominance
No dominance
Lisinopril (ACE Inhibitor) Outcomes

for Hypertensive heart disease

Efficacy Outcomes
Overall Effectiveness
+88%
Response Rate
+75%
Common Side Effects
Cough
+20%
Dizziness
+10%
Hyperkalemia
+5%
Angioedema
+0.7%

Sources:

nih.gov
consensus.app
researchgate.net

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

FIX IT
Active Clinical Trials
1 active trial recruiting for Lisinopril (ACE Inhibitor) in Hypertensive heart disease

Effect of Sacubitril/Valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study

NCT05498675RECRUITING
View Study
180 participants
OBSERVATIONAL
Beijing, China
Started: Sep 1, 2021
Completed Clinical Trials
1 completed trial for Lisinopril (ACE Inhibitor) in Hypertensive heart disease

The CLEVER Study - Coreg And Left Ventricular Mass Regression

NCT00108082COMPLETEDPHASE3
View Study
287 participants
INTERVENTIONAL
Birmingham, United States +77 more
Started: Jan 1, 2005